Hu et al. [1] conducted a retrospective cohort study to assess the impact of MRI risk assessment on the survival benefits of neoadjuvant chemoradiotherapy (nCRT) in patients with stage II-III rectal cancer. The study aimed to evaluate whether MRI findings could help predict the outcomes of nCRT and assist in tailoring personalized treatment plans. They categorized patients based on MRI risk factors to predict its effect on long-term survival. The findings of this study indicated that MRI-based r…